Angiogenesis in multiple myeloma - Clinical implications;Angiogeneza w szpiczaku mnogim - Implikacje kliniczne

Acta Haematologica Polonica

Volumn 38, Issue 2, 2007, Pages 177-186

  Mordak Domagała, Monika ^a   Kuliszkiewicz Janus, Małgorzata ^b  

^a Dolnoslaskie Centrum Transplantacji Komorkowych z Krajowym Bankiem Dawcow Szpiku   (Poland)

^b Katedra i Klinika Hematologii   (Poland)

Author keywords

Angiogenesis; Multiple myeloma

Indexed keywords

ANGIOGENESIS INHIBITOR; CYTOKINE; ENDOTHELIAL CELL GROWTH FACTOR; VASCULOTROPIN;

ANGIOGENESIS; CELL GROWTH; CELL PROLIFERATION; HEMATOPOIETIC STEM CELL; HUMAN; MULTIPLE MYELOMA; NEOVASCULARIZATION (PATHOLOGY); REVIEW;

EID: 34548593785     PISSN: 00015814     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Bussolino F, Albini A., Camussi G. et al. Role of soluble mediators in angiogenesis. Eur J Cancer 1996; 32A: 2401-2412
2. Chauhan D, Catley L, Hideshima T. et al. 2-Methoxyestradiol overcomes drug resistence in multiple myeloma cells. Blood 2002; 100: 2187-2194
3. Ciepluch H, Baran W, Helleman A. Combination of pamidronate and thalidomide in the therapy of treatment-resistant multiple myeloma. Med Sci Monit 2002; 8(4): 31-36
4. Davies FE, Raje N, Hideshima T, Lentzsch S, Young G, Tai YT, Lin B, Podar K, Gupta D, Chauhan D, Treon SP, Richardson PG, Schlossman RL, Morgan GJ, Muller GW, Striling DI, Anderson KC. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001; 981: 210-216
5. Dmoszynska A, Bojarska-Junak A, Domanski D, Rolinski J, Hus M, Sroka-Wojtaszko M. Production of proangiogenic cytokines during thalidomide treatment of multiple myeloma. Leuk Lymphoma 2002; 43 (2):401-6
6. Dmoszynska A, Rolinski J, Bojarska-Junak A, Manko J, Jawniak D, Walter-Croneck A, Soroka-Wojtaszko M, Hus M. Influence of thalidomide on Bcl2 expression and proangiogenic cytokine levels in short-term culture of peripheral blood and bone marrow mononuclear cells of multiple myeloma patients. Pol J Pharmacol 2001; 53 (6): 709-13
7. Dvorak HF., Nagy JA., Feng D., Brown FL., Dvorak AM. Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular permeability in angiogenesis. Curr Top Microbiol 1999; 237: 97-132
8. Ellis LM, Fidler IJ. Angiogenesis and metastasis. Eur J Cancer 1996; 32A: 2451-2460
9. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev; 1997; 18: 4-25
10. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Med 1995; 1: 27-31
11. Folkman J. Tumor angiogenesis. In: Holland JR, Frei E, Bast R, Kufe D, Morton D, Weichselbaum R, eds; Cancer Medicine; 4 th ed. Baltimore: Wiliams & Wilkins; 1996; 181-204.
12. Folkman J, Shing Y.Angiogenesis. J Biol Chem 1992; 267: 10931-10934
13. Hatfield KJ, Olsnes AM, Gjertsen BT, Bruserud O. Antiangiogenic therapy in acute myelogenous leukemia: targeting of vascular endothelial growth factor and interleukin 8 as possible antileukemic strategies. Curr Cancer Drug Targets. 2005; 5(4): 229-48.
14. Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, Zagzag D, Yancopoulos GD, Wiegand SJ. Vessel cooption, regression and growth in tumors mediated by angiopoietins and VEGF. Science 1999; 284: 1994-1998
15. Hus M, Dmoszynska A, Soroka-Wojtaszko M, Jawniak D, Legiec W, Ciepnuch H, Hellmann A, Wolska-Smolen T, Skotnicki A, Manko J. Thalidomide treatment of resistant or relapsed multiple myeloma patients. Haematologica 2001; 86(4): 404-8.
16. Iruela-Aripse M., Dvorak H. Angiogenesis: a dynamic balance of stimulators and inhibitors. Thromb Haemost 1997; 78: 672-677.
17. Kelly T, Borset M. et al. Matrix metalloproteinase in multiple myeloma. Leukemia et lymphoma 2000; 37: 273-281.
18. Klein B, Zhang XG, Lu ZY, Bataille R. Interleukin-6 in human multiple myeloma. Blood 1995; 85: 863-872.
19. Kryczek I, Lange A, Mottram P, Alvarez X, Cheng P et al. CXCL12 and Vascular Endothelial Growth Factor synergistically induce neoangiogenesis in human ovarian cancers. Cancer Res 2005; 65 (2).
20. Kumar S, Rajkumar SV. Thalidomide and lenalidomide in the treatment of multiple myeloma. Eur J Cancer. 2006; 42(11): 1612-1622.
21. Lin B, Podar K, Gupta D, Tai YT, Li S, Weller E, Hideshima T, Lentzsch S, Davies F, Li C, Weisberg E, Schlossman RL, Richardson PG, Griffin JD, Wood J, Munshi NC, Anderson KC. The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment. Cancer Res. 2002; 62(17): 5019-26.
22. Mitsiades N, Mitsiades CS. Poulaki V, et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002; 99: 4524-4530.
23. Mooberry SL. New insights into 2-methoxyestradiol, a promising antiangiogenic and antitumor agent. Curr Opin Oncol. 2003; 15(6): 425-30.
24. Raffi S. Circulating endothelial precursors. J Clin Invest 2000; 105: 17-19.
25. Rajkumar SV, Mesa RA, Foncesa R, Schroeder G, Plevak M, Dispenzieri A, Lacy MQ, Lust JA, Witzig TE, Gertz MA, Kyle RA, Russell SJ, Greipp PR. Bone marrow angiogenesis in 400 patients with Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma and Primary Amyloidosis. Clin Cancer Res 2002; 8: 2210-2216.
26. Rajkumar SV, Leong T, Roche PC, Fonseca R, Dispenzieri A, Lacy MQ, Lust JA, Witzig TE, Kyle RA, Gertz MA, Greipp PR. Prognostic value of bone marrow angiogenesis in mutiple myeloma. Clin Cancer Res 2000; 6: 3111-3116.
27. Rajkumar SV, Foncesa R., Witzig TE., Gertz MA., Greipp PR. Bone marrow angiogenesis in patients achieving completae response after stem cell transplantation for multiple myeoloma. Leukemia 1999; 13: 469-472.
28. Rajkumar SV. Current status of thalidomide in the treatment of cancer. Oncology 2001; 15: 67-874.
29. Rajkumar SV, Gertz MA, Lacy MQ. et al. Thalidomide as initial therapy for early-stage myeloma. Leukemia 2003; 17: 775-779.
30. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin DH, Rajkumar SV, Srkalovic G, Alsina M, Anderson KC. Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma: final time-to-event results from the SUMMIT trial. Cancer. 2006; 106(6): 1316-9.
31. Sezer O, Niemooler K, Kaufmann O, Eucker J, Jakob C, Zavrski I, Possinger K. Decrease of bone marrow angiogenesis in myeloma patients achieving a remission after chemotherapy. Eur J Haematol 2002; 66: 238-244.
32. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, Zeddis J, Barlogie B. Antitumor activity of thalidomide in refractory multiple myeloma. N Eng J Med 1999; 341: 1565-1571.
33. Tosi P, Zampagni E., Cellini C. et al. Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma. Haematologica 2002; 87: 408-414.
34. Vacca A, Ribatti D, Roncali L, Ranieri G, Serio G, Silvestris F, Dammacco F. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 1994; 87: 503-508.
35. Weber D., Rankin K., Gavino M. et al. Thalidomide alone or wyth dexamethason for previously untreated multiple myeloma. J Clin Oncol 2003; 21: 16-19.
36. Wolowiec D, Wozniak Z, Potoczek S, Ganczarski G, Wrobel T, Kuliczkowski K, Frydecka I, Jelen M. Bone marrow angiogenesis and proliferation in B-cell chronic lymphocytic leukemia. Anal Quant Cytol Histol. 2004; 26(5): 263-70.
37. Wrobel T, Mazur G, Surowiak P, Wołowiec D, Jelen M, Kuliczkowsky K. Increased expression of vascular endothelial growth factor (VEGF) in bone marrow of patients with myeloproliferative disorders (MPD). Pathol Oncol Res 2003; 9(3): 170-3.
38. Zangari M, Anaissie E, Stopeck A. et al. Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma. Clin Cancer Res 2004; 10: 88-95.